RI-AG03 (acetate)
RI-AG03 acetate is the acetate of RI-AG03. RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease[1][2].
Product Specifications
UNSPSC
12352209
Target
Tau Protein
Related Pathways
Neuronal Signaling
Field of Research
Neurological Disease
Purity
98.22
Solubility
DMSO : 2.5 mg/mL (ultrasonic)
Smiles
[Ac-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-Gly-{d-Pro}-{d-Lys}-{d-Tyr}-{d-Lys}-{D-Ile}-{d-Gln}-{d-Val}-Gly-{d-Arg}-NH2(acetatesalt)]
Molecular Formula
C104H189N49O22·xC2H4O2
Molecular Weight
2477.93 (free base)
References & Citations
[1]Di Natale G, et al. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease? Molecules. 2022 Aug 9;27 (16) :5066.|[2]Aggidis A, et al. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20 (11) :7788-7804.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
